ACE-031 Peptide: Research Guide, Mechanism & Vendor Tips (2026)

ACE-031 sits in an unusual spot in the research compound universe. It's not a peptide in the traditional sense — it's a massive recombinant fusion protein weighing in at around 100–130 kDa, produced through mammalian cell expression systems rather than standard solid-phase peptide synthesis. And yet it shows up constantly in peptide research forums and biohacking discussions because of what it does: it intercepts myostatin, the body's primary brake on muscle growth.

The science behind it is genuinely compelling. Animals and humans with natural myostatin deficiencies develop dramatically increased muscle mass — think Belgian Blue cattle with their absurdly muscled frames, or the handful of documented human cases with myostatin gene mutations who exhibit extraordinary musculature without training. ACE-031 was designed to pharmacologically replicate that effect. It got far enough to produce real human clinical data before vascular side effects shut the program down.

What Is ACE-031? Beyond the Basics

ACE-031 — formally known as ramatercept (CAS 1621169-52-5) — is a recombinant fusion protein engineered from two functional components: the ligand-binding domain of the human activin receptor type IIB (ACVR2B) fused to the Fc region of human IgG1. This design gives the molecule a dual purpose — it acts as a decoy receptor, intercepting myostatin and a cluster of related signaling proteins before they can bind to and activate their native receptors on muscle and bone cells.

The Myostatin Connection

Myostatin (growth differentiation factor 8, or GDF-8) is a member of the TGF-β superfamily and is one of the most well-characterized negative regulators of skeletal muscle mass. It's basically a biological governor that prevents muscles from growing beyond a certain point. Remove it — genetically or pharmacologically — and muscle mass increases dramatically.

Why a Fusion Protein Instead of a Simple Peptide

ACE-031 was developed by Acceleron Pharma specifically because short peptides couldn't capture myostatin effectively enough. The ACVR2B domain needed to be large enough to maintain the natural receptor's binding geometry, and the IgG1-Fc tail was added to extend half-life from minutes to days. You can't achieve this with a 15-amino-acid synthetic peptide — hence the complexity and cost of production.

The Broader Ligand Trap

Because ACVR2B binds not only myostatin but also activin A, activin B, GDF-11, and BMP-9, ACE-031 has a broader scope of action than simple myostatin-only blockers. This broader ligand capture may explain both its potent anabolic effects and some of its off-target findings in clinical data. It's a double-edged sword: more potent, but less predictable.

How ACE-031 Works: The Decoy Receptor Mechanism

Understanding how ACE-031 operates requires a look at the ACVR2B signaling pathway. In healthy muscle tissue, myostatin binds to the ACVR2B receptor on muscle satellite cells, initiating a SMAD2/3 signaling cascade that suppresses protein synthesis and promotes muscle atrophy. ACE-031 intervenes upstream of this entire process.

The Ligand Trap in Action

When administered, ACE-031 circulates in the bloodstream and functions as a ligand trap — its ACVR2B domain has a higher binding affinity for myostatin and related ligands than the native membrane-bound receptor does. By sequestering these ligands in circulation, ACE-031 prevents them from ever reaching muscle cells. The IgG1-Fc fusion region extends the molecule's half-life significantly (estimated at several days to weeks in human pharmacokinetic studies), making it suitable for infrequent dosing.

Downstream Effects on SMAD Signaling

With myostatin and activins removed from circulation, the SMAD2/3 pathway in muscle cells isn't activated. This releases the brake on Akt/mTOR-mediated protein synthesis, allowing muscle fibers to increase protein production and grow. It's removing a suppressor rather than adding a stimulator — an important mechanistic distinction from growth hormone-based approaches.

What Gets Captured Besides Myostatin

ACE-031 doesn't just grab myostatin. It also neutralizes:

• Activin A and B: Involved in reproductive signaling, erythropoiesis, and bone remodeling
• GDF-11: A factor with complex roles in aging, tissue maintenance, and regeneration
• BMP-9 and BMP-10: Critical for vascular endothelial homeostasis — this is where the safety problems came from

Clinical Trial Results: What Actually Happened in Humans

ACE-031 progressed to human clinical trials, which is noteworthy for a research compound of this complexity. The data that exists is genuinely informative.

Phase 1: Healthy Volunteers

A Phase 1 single ascending-dose study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamic effects in healthy volunteers (Attie et al., 2013, Muscle Nerve). Key findings:

• Tolerability: Generally well-tolerated. Most common adverse event was injection site erythema
• Pharmacokinetics: AUC and Cmax increased in dose-proportional manner — predictable, linear kinetics
• Lean mass: Even in the single-dose format, measurable increases in lean body mass were detected at higher dose levels
• Bone biomarkers: Changes in bone formation and resorption markers detected, suggesting bone metabolism effects

Phase 2: Duchenne Muscular Dystrophy

Acceleron conducted Phase 2 trials in patients with Duchenne muscular dystrophy. These trials demonstrated genuine pharmacological activity — increases in lean body mass, reductions in fat mass, and some improvements in muscle volume on imaging.

But then the problems emerged. Participants developed epistaxis (nosebleeds), gum bleeding, and skin telangiectasias (dilated small blood vessels visible under the skin). These vascular effects were traced to BMP-9/BMP-10 inhibition through ALK1 receptor disruption — essentially, ACE-031 was pharmacologically recreating aspects of hereditary hemorrhagic telangiectasia (HHT), a genetic vascular condition (Campbell et al., 2017).

The program was subsequently discontinued. No Phase 3 trials were initiated.

ACE-031 Effects on Muscle Growth

The Anabolic Potential

The Phase 1 data confirmed what animal studies had suggested: blocking the myostatin pathway produces measurable muscle growth in humans. Even a single dose of ACE-031 at the higher dose levels produced detectable increases in lean body mass — an extraordinary finding that validated decades of myostatin research in a clinical setting.

Preclinical Muscle Data

In animal models, ACE-031 produced substantial increases in skeletal muscle mass, with some studies showing 20–30% increases in muscle fiber cross-sectional area. These preclinical results were consistent across multiple species and study designs, establishing a robust evidence base for the mechanism (Cadena et al., 2010).

Comparison to GH-Pathway Approaches

ACE-031's muscle-building mechanism is fundamentally different from growth hormone secretagogues. GH peptides like ipamorelin and CJC-1295 stimulate muscle growth by increasing GH and IGF-1 levels — they step on the accelerator. ACE-031 releases the brake. These are complementary but mechanistically distinct approaches, operating on entirely separate receptor systems. For more on the best peptides for muscle growth, see our dedicated guide.

Effects on Bone Density and Metabolism

Bone Formation Data

Preclinical rodent models showed increased bone mineral density and trabecular bone volume with ACE-031 treatment. Human Phase 1 data confirmed changes in bone formation and resorption biomarkers, suggesting clinical relevance to osteoporosis research (Attie et al., 2013).

Metabolic Effects

Some animal studies noted reductions in fat mass alongside increases in lean tissue — a body recomposition effect attributed to the multifactorial role of activin signaling in energy metabolism. This makes ACE-031 interesting beyond pure muscle biology — it touches metabolic pathways that could be relevant to obesity and diabetes research.

ACE-031 vs. Other Myostatin Pathway Modulators

ACE-031 vs. Follistatin

Follistatin is a naturally occurring glycoprotein that binds and neutralizes myostatin and activins. It's sometimes compared to ACE-031 due to similar broad-spectrum ligand capture, but it's a naturally occurring protein rather than an engineered fusion construct. Delivery methods and pharmacokinetics differ significantly. For a detailed comparison of myostatin-pathway approaches, see our guide on bimagrumab vs. follistatin.

ACE-031 vs. Apitegromab

Apitegromab represents the next generation of myostatin-targeting — a selective monoclonal antibody that binds only proMyostatin and latent myostatin, leaving activins and BMPs untouched. This avoids the vascular complications that killed ACE-031's program. Apitegromab is in Phase 3 trials for SMA as of 2026, demonstrating that selectivity matters more than potency in this pathway.

ACE-031 vs. Growth Hormone Peptides

Compared to bodybuilding peptides like MK-677 or Ipamorelin that work via the growth hormone axis, ACE-031 operates through an entirely separate pathway — making them mechanistically distinct. GH peptides increase anabolic signaling; ACE-031 removes catabolic signaling. Theoretically complementary, but no human safety data exists for combinations.

Sourcing and Quality Verification Challenges

ACE-031 presents unique sourcing challenges that go well beyond what you'd encounter with a standard peptide like BPC-157 or TB-500.

Why Sourcing Is Particularly Difficult

Because ACE-031 is a large recombinant fusion protein, its production requires mammalian cell expression systems — Chinese Hamster Ovary (CHO) cells or similar platforms. This is orders of magnitude more complex and expensive than standard solid-phase peptide synthesis. The quality control challenge in unregulated markets is enormous.

Analytical Verification Methods

A 2025 study published in Drug Testing and Analysis examined black-market ACE-031 samples using gel electrophoresis and LC-MS/MS tryptic digest analysis. Some samples contained the correct protein; others showed contamination, degradation, or misrepresented concentrations (PubMed).

What to Look For

• Third-party COA with SDS-PAGE data confirming correct molecular weight band (~100–130 kDa)
• HPLC purity data showing >95% purity
• Endotoxin testing results (critical for protein-based compounds)
• Cold-chain shipping with appropriate lyophilized format
• Pricing that reflects legitimate production costs — suspiciously cheap ACE-031 is almost certainly not genuine

Legal Status and Regulatory Considerations

Not Approved for Human Use

ACE-031 is not approved by the FDA or any major regulatory agency for human therapeutic use. Its clinical development was paused before Phase 3 trials. In most countries, it exists as a research chemical — legal to purchase for legitimate laboratory research but not for human consumption.

Anti-Doping Status

ACE-031 is banned by WADA under hormone and metabolic modulators. Detection methods including LC-MS/MS tryptic digest approaches are actively being developed and validated for anti-doping testing.

Regulatory Complexity for Biologics

Unlike small-molecule research chemicals, large fusion proteins like ACE-031 may face different regulatory scrutiny depending on jurisdiction. Researchers should verify local regulations regarding recombinant proteins and biologics before procurement.

Safety Profile: What We Know

Phase 1 Safety Data

In healthy volunteers, injection site erythema was the most common adverse event. No serious adverse events were reported at the doses studied. Pharmacokinetics were predictable and linear.

Phase 2 Safety Concerns

The DMD Phase 2 trials revealed the critical safety issues: epistaxis, gum bleeding, and telangiectasias. These vascular effects were mechanistically traced to BMP-9/BMP-10 sequestration, which disrupts ALK1 signaling essential for vascular endothelial homeostasis.

Theoretical Long-Term Concerns

Beyond vascular effects, broad inhibition of activin A and B raises theoretical concerns across reproductive endocrinology, erythropoiesis, bone remodeling, and multiple organ systems. The full downstream consequences of sustained pan-ActRIIB inhibition in humans remain uncharacterized.

Research Applications and Potential

Muscle-Wasting Diseases

Despite the safety concerns, the concept of myostatin pathway inhibition remains highly relevant to sarcopenia, cachexia, and muscular dystrophies. The field has moved toward more selective agents, but ACE-031's clinical data validated the approach.

Bone Research

The bone density effects observed in preclinical and early clinical data suggest potential relevance to osteoporosis research. Dual muscle-bone anabolic effects make myostatin pathway modulation an attractive research target for conditions where both tissues are affected simultaneously.

Academic and Tool Compound Value

ACE-031 remains valuable as a research tool for studying the ACVR2B signaling network. Its broad ligand capture makes it useful for experiments designed to understand the integrated effects of simultaneously blocking multiple TGF-β superfamily members.

Frequently Asked Questions About ACE-031